DailyClout
0
  • Home
  • Billcam
  • Communities
  • Submissions
  • Events
  • Our Story
  • Shop
  • Donate
  • Become a Member!
  • Login/Sign Up
  • Home
  • Billcam
  • Communities
  • Submissions
  • Events
  • Our Story
  • Shop
  • Donate
  • Become a Member!
  • Login/Sign Up
  • All Posts
  • Bulletin Board
  • DailyClout Lawsuit
  • Opinion
  • Pfizer Reports
  • The Mindful Activist
  • Contributors

DailyClout Pfizer Reports

Report 65: In the First Three Months of Pfizer’s mRNA “Vaccine” Rollout, Nine Patients Died of Anaphylaxis. 79% of Anaphylaxis Adverse Events Were Rated as “Serious.”

March 31, 2023 • by Joseph Gehrett, MD; Barbara Gehrett, MD; Chris Flowers, MD; and Loree Britt

The War Room/DailyClout Pfizer Documents Analysis Project Post-Marketing Group (Team 1) – Joseph Gehrett, MD; Barbara Gehrett, MD; Chris Flowers, MD; and Loree Britt – produced an shocking review of anaphylaxis (severe allergy reaction) adverse events found in Pfizer document 5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-FEB-2021 (a.k.a., “5.3.6“). Severe allergic reaction is typically triggered by latex, foods such as peanuts, bee stings, or medications (injected or taken by mouth), among other things, and is generally considered a medical emergency.

It is important to note that the adverse events (AEs) in the 5.3.6 document were reported to Pfizer for only a 90-day period starting on December 1, 2020, the date of the United Kingdom’s public rollout of Pfizer’s COVID-19 experimental mRNA “vaccine” product.

Key points in this report include:

  • There were nine reported deaths.

    • Only four patients who died were reported to have serious, underlying medical conditions that “likely contributed to their deaths.”
  • There were 1,833 potential anaphylaxis patients reported; but, after screening using a tool called Brighton Collaboration, 831 did not meet anaphylaxis criteria, leaving 1,002 cases reported in 90 days. Pfizer reported 2,958 “potentially relevant events” from those 1,002 individuals that included the signs and symptoms of anaphylaxis.

    • Where did the other 831 patients and their allergic adverse events go/get assigned in the post-marketing data, if anywhere?

  • Pfizer reported only the most frequent anaphylaxis signs and symptoms: anaphylactic reaction (435), shortness of breath (356), rash (190), redness of the skin (159), hives (133), cough (115), respiratory distress (97), throat tightness (97), swollen tongue (93), low blood pressure (72), low blood pressure severe enough to threaten organ function (shock) (80), chest discomfort (71), swelling face (70), throat swelling (68), and lip swelling (64).

  • The events were rated as serious in 2,341 (79%) and non-serious in 617 (21%).

  • The ratio of females to males affected was over 8:1. Of those cases with gender specified, 876 (89%) were female, 106 (11%) were male.

  • Half of patients with this adverse event were younger than 43.5 years old.

  • Pfizer’s Conclusion: Evaluation of BC (Brighton Collaborative) cases Level 1-4 did not reveal any significant new safety information. Anaphylaxis is appropriately described in the product labeling as are non-anaphylactic hypersensitivity events. Surveillance will continue.

Read this important two-page report below:

Post-Marketing Anaphylaxis microreport - p1
https://dailyclout.io/wp-content/uploads/Post-Marketing-Anaphylaxis-microreport-p1.pdf
Post-Marketing Anaphylaxis microreport - p2
https://dailyclout.io/wp-content/uploads/Post-Marketing-Anaphylaxis-microreport-p2-1.pdf

Pre-Order Your Copy of the Pfizer Reports Paperback Book.
Please support DailyClout.
Become a DailyClout Member.

Spread the love
Spread the love
#Pfizer #Safety allergic reaction allergies anaphylaxis Brighton Collaboration clinical trial cough death drug safety female hives low blood pressure medical emergency medical safety pfizer clinical trial post-marketing postmarketing rash redness of skin respiratory respiratory distress severe allergic reaction shock shortness of breath swelling women
Previous StoryThis is The New Beginning of Real Medicine
Next StoryVax Death Count = COVID Death Count, According to Latest Rasmussen Reports Poll

1 reply added

  1. Generation X April 12, 2023 Reply

    Humans are the test subjects of the experiment and products. The longevity project or reverse aging process (life extension) also uses the same technology. There are several companies that are working on this technology. Ability to slow down and reverse aging is the goal. It’s what makes sense if you think about it.

Leave your comment Cancel Reply

(will not be shared)

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Recent Posts

  • letter
    To the Editor: Arkansas Senator Tom Cotton on the WHO Attempt to Overtake All Nations Friday, 9, Jun
  • image
    COS Action President Mark Meckler Responds to Gov. Gavin Newsom’s Call for Article 5 Convention to Add Gun Control Amendment to Constitution Friday, 9, Jun
  • dc beef
    Beef Company CEO: Non-Compliance Is the Only Way to Stop Attacks on Real Meat Friday, 9, Jun
  • hummingbird
    AI and the Decision to Stay Human Friday, 9, Jun
  • Screenshot 2023-06-09 2.39.38 PM
    Dr. Jen VanDeWater on One Wellness, Hormonal Balance, and the Importance of the Voices of Patients Friday, 9, Jun

Blog Archive

Subscribe to Our Newsletter

  • I agree to receive emails and other content from DailyClout. I understand that I may repeal my consent at any time.

  • Home
  • Contact Us
  • BillCam
  • Communities
  • About Us
  • Submissions
  • Advertise with Us
  • Events
View Cart Checkout
Do you really want to logout of DailyClout?
Yes

You are now leaving DailyClout...